Interventions in infectious diseases can have both direct effects on individuals who receive the intervention as well as indirect effects in the population. In addition, intervention combinations can have complex interactions at the population level, which are often difficult to adequately assess with standard study designs and analytical methods.
Herein, we urge the adoption of a new paradigm for the design and interpretation of intervention trials in infectious diseases, particularly with regard to emerging infectious diseases, one that more accurately reflects the dynamics of the transmission process. In an increasingly complex world, simulations can explicitly represent transmission dynamics, which are critical for proper trial design and interpretation. Certain ethical aspects of a trial can also be quantified using simulations. Further, after a trial has been conducted, simulations can be used to explore the possible explanations for the observed effects.
Much is to be gained through a multidisciplinary approach that builds collaborations among experts in infectious disease dynamics, epidemiology, statistical science, economics, simulation methods, and the conduct of clinical trials.
Ross R. An application of the theory of probabilities to the study of a priori pathometry. Part 1. Proc R Soc Series A. 1916;92:204–30. CrossRef
Baird S, Bohren J, McIntosh C, Özler B. Optimal design of experiments in the presence of interference. Review of Economics and Statistics. Accepted August 7, 2017. doi: 10.1162/REST_a_00716, in Press.
Ebola ca Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015;351:h3740. PubMedCentral
Hitchings M, Grais R, Lipsitch M. Using simulation to aid trial design: ring-vaccination trials. PLoS Negl Trop Dis. 2017;11(3):e0005470. https://doi.org/10.1371/journal.pntd.0005470. CrossRefPubMedPubMedCentral
Longini I, Halloran M. A frailty mixture model for estimating vaccine efficacy. Appl Stat. 1996;45:165–73. CrossRef
National Academies of Sciences, Engineering, and Medicine. Integrating Clinical Research into Epidemic Response: The Ebola Experience. Washington, DC: The National Academies Press; 2017.
Berry D. Bayesian clinical trials. Drug discovery. Nature Rev. 2006;5(1):27–36.
Robotham J, Graves N, Cookson B, Barnett A, Wilson J, Edgeworth J, Batra R, Cuthbertson B, Cooper B. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011;343:5694. doi: 10.1136/bmj.d5694. CrossRef
Churchyard G, Fielding K, Lewis J, Coetzee L, Corbett EL, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Eng J Med. 2014;370:301–10. CrossRef
Orroth K, White R, Korenromp E, Bakker R, Changalucha J, Habbema J, Hayes R. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis. 2006;33(9):536–44. CrossRefPubMed
Ali M, Sur D, You Y, et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata. India Clin Inf Dis. 2013;56:1123–31. CrossRef
McCormick A, Abuelezam N, Rhode E, Hou T, Walensky R, et al. Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One. 2014;9(5):e98272. doi: 10.1371/journal.pone.0098272. CrossRefPubMedPubMedCentral
Staples P, Prague M, DeGruttola V, Onnela J. Leveraging contact network information in cluster randomized trials of infectious processes. 2016. arXiv:1610.00039 [stat.AP]. arXiv.org.
- Simulations for designing and interpreting intervention trials in infectious diseases
M. Elizabeth Halloran
Nicole E. Basta
Steven E. Bellan
Ben S. Cooper
James P. Hughes
Eric T. Lofgren
Ira M. Longini
George R. Seage
Thomas A. Smith
- BioMed Central
Neu im Fachgebiet Allgemeinmedizin
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II